

**Rh(II)-catalyzed three-component reaction of 3-diazo oxindoles with
N,N-disubstituted anilines and glyoxylates for the synthesis of 3-aryl-
3-substituted oxindoles**

Shi-Kun Jia, Long-Long Song, Yu-Bing Lei, A. Gopi Krishna Reddy, Dong Xing and

Wen-Hao Hu*

Shanghai Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal
University, 3663 North Zhongshan Road, Shanghai 200062, China

E-mail: whu@chem.ecnu.edu.cn.

Table of Contents

General Information and Materials	S2
General Procedure for Optimization of Reaction Conditions	S3-S4
Characterization Data of Compounds	S5-S13
X-ray Diffraction Parameters and Data of <i>syn</i>-4d	S14
NMR Spectra of Compounds	S15-S38

General Information and Materials

All ^1H NMR (400 MHz) and ^{13}C NMR (100 MHz) and ^{19}F NMR (376 MHz) spectra were recorded on Brucker spectrometers in CDCl_3 . Tetramethylsilane (TMS) served as an internal standard ($\delta = 0$) for ^1H NMR, and CDCl_3 was used as internal standard ($\delta = 77.0$) for ^{13}C NMR. Chemical shifts are reported in parts per million as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad). High-resolution mass spectrometry (HRMS) was performed on IonSpec FT-ICR or Waters Micromass Q-TOF micro Synapt High Definition Mass Spectrometer. HPLC analysis was performed on Dalian Elite (UV230+ UV/Vis Detector and P230P High Pressure Pump). Melting points were uncorrected. Single crystal X-ray diffraction data (*syn-4d*) were recorded on Bruker-AXS SMART APEX II single crystal X-ray diffractometer. Yields for all compounds were combined yields for all isomers unless otherwise indicated.

All reactions and manipulations were carried out under an argon atmosphere in a flame-dried or oven-dried flask containing magnetic stir bar. Dichloromethane (DCM), 1,2-dichloroethane (DCE), CHCl_3 and toluene was distilled over calcium hydride. Solvents for the column chromatography were distilled before use. 4 Å molecular sieves was dried in a Muffle furnace at 250 °C over 5 hrs.

General Procedure for Optimization of Reaction Conditions


General procedure for optimization of reaction conditions (Table 1)

A mixture of $\text{Rh}_2(\text{OAc})_4$ (0.001 mmol), **1a** (0.13 mmol) (as indicated in Table 1), **3a** (0.2 mmol) (50 wt. % solution in toluene) and 4 Å MS (100 mg) in 1mL of solvent under an argon atmosphere was stirred under T. Diazo compound **2a** (0.1 mmol) in 1 mL of solvent was then added over 1 h via a syringe pump. After completion of the addition, the reaction mixture was stirred for another 0.5 h, then filtrated and evaporated *in vacuo* to give the crude product. The crude products was purified by flash chromatography on silica gel ($\text{EtOAc}/\text{light petroleum ether} = 1:10 \sim 1:5$) to give the pure product.

General procedure for the preparation of products (Scheme 2)


A mixture of $\text{Rh}_2(\text{OAc})_4$ (0.003 mmol), **1** (0.33 mmol), **3** (0.6 mmol) and 4 Å MS (100 mg) in 1 mL of DCM under an argon atmosphere was stirred at rt. Diazo compound **2** (0.3 mmol) in 1 mL or 2 mL of DCM was then added over 1 h via a syringe pump. After completion of the addition, the reaction mixture was stirred for another 0.5 h, then filtrated and evaporated *in vacuo* to give the crude product. The crude products was purified by flash chromatography on silica gel ($\text{EtOAc}/\text{light petroleum ether} = 1:10 \sim 1:5$) to give the pure product.

Procedure for the control experiment




A mixture of $\text{Rh}_2(\text{OAc})_4$ (0.001 mmol), **5a** (0.1 mmol), **3a** (0.2 mmol) and 4 Å MS (100 mg) in 1 mL of DCM under an argon atmosphere was stirred at rt for 2 h, the **4a** was not found.

Procedure for the gram-scale experiment



A mixture of $\text{Rh}_2(\text{OAc})_4$ (0.03 mmol), **1a** (4 mmol), **3a** (6 mmol) (50 wt. % solution in toluene) and 4 Å MS (100 mg) in 3 mL of DCM under an argon atmosphere was stirred at rt. Diazo compound **2a** (3 mmol) in 2 mL of DCM was then added over 1 h via a syringe pump. After completion of the addition, the reaction mixture was stirred for another 0.5 h, then filtrated and evaporated in *vacuo* to give the crude product. The crude products was purified by flash chromatography on silica gel ($\text{EtOAc}/\text{light petroleum ether} = 1:10 \sim 1:5$) to give the pure product **4a** (1.52 g, 85%).


Procedure for intermolecular kinetic isotope effect experiment.



A mixture of $\text{Rh}_2(\text{OAc})_4$ (0.003 mmol), **1a** (0.3 mmol), **[D₅]-1a** (0.3 mmol), **3a** (0.6 mmol) and 4 Å MS (100 mg) in 1 mL of DCM under an argon atmosphere was stirred at rt. Diazo compound **2** (0.33 mmol) in 1 mL of DCM was then added over 1 h via a syringe pump. After completion of the addition, the reaction mixture was stirred for another 0.5 h, then filtrated and evaporated *in vacuo* to give the crude product. The crude products was purified by flash chromatography on silica gel ($\text{EtOAc}/\text{light petroleum ether} = 1:10 \sim 1:5$) to give the crude product, the crude mixture was then subjected to ¹H NMR analysis for the determination of the ratio between **4e** and **4e-d₄**.


Characterization Data of Compounds

(S)-ethyl 2-((R)-1-benzyl-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate



¹H NMR (400 MHz, CDCl₃) δ 7.46 – 7.08 (m, 19H), 7.05 – 6.93 (m, 1H), 6.77 – 6.53 (m, 3H), 5.13 (d, *J* = 9.4 Hz, 1H), 5.05 (d, *J* = 15.8 Hz, 1H), 4.75 (d, *J* = 15.9 Hz, 1H), 4.62 (s, 4H), 4.09 – 3.83 (m, 2H), 3.53 (d, *J* = 9.4 Hz, 1H), 0.86 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 177.29, 172.19, 148.49, 143.79, 138.49, 135.57, 128.82, 128.74, 128.68, 128.54, 127.51, 127.27, 127.24, 126.99, 126.64, 126.15, 123.43, 122.18, 112.24, 109.68, 75.43, 61.31, 58.55, 54.33, 44.07, 13.58. HRMS (ESI) Calcd. for C₃₉H₃₆N₂NaO₄ (M+Na)⁺ 619.2573, found: 619.2542.


(S)-ethyl 2-((R)-3-(4-(dibenzylamino)phenyl)-1-methyl-2-oxoindolin-3-yl)-2-hydroxyacetate



syn-4b

¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.26 (m, 7H), 7.25 – 7.17 (m, 7H), 7.11 – 7.03 (m, 1H), 6.85 (d, *J* = 7.8 Hz, 1H), 6.64 (d, *J* = 8.9 Hz, 2H), 5.03 (d, *J* = 9.7 Hz, 1H), 4.62 (s, 4H), 4.05 – 3.73 (m, 2H), 3.60 (d, *J* = 9.7 Hz, 1H), 3.20 (s, 3H), 0.88 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 177.20, 172.06, 148.45, 144.61, 138.45, 128.94, 128.65, 128.47, 127.37, 126.96, 126.60, 126.04, 123.36, 122.20, 112.18, 108.52, 75.52, 61.19, 58.14, 54.31, 26.49, 13.60. HRMS (ESI) Calcd. for C₃₃H₃₂N₂NaO₄ (M+Na)⁺ 543.2260, found: 543.2234.


(R)-benzyl 3-(4-(dibenzylamino)phenyl)-3-((S)-2-ethoxy-1-hydroxy-2-oxoethyl)-2-oxoindoline-1-carboxylate



syn-4c

¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.15 (m, 19H), 7.06 – 6.98 (m, 1H), 6.74 – 6.60 (m, 3H), 5.13 (d, *J* = 9.4 Hz, 1H), 5.05 (d, *J* = 15.9 Hz, 1H), 4.76 (d, *J* = 15.9 Hz, 1H), 4.63 (s, 4H), 4.04 – 3.84 (m, 2H), 3.51 (d, *J* = 9.4 Hz, 1H), 0.86 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 176.89, 171.89, 148.27, 142.29, 135.09, 133.69, 129.36, 128.81, 128.69, 128.19, 127.66, 127.16, 126.48, 122.09, 116.03, 112.12, 110.51, 75.25, 61.48, 58.69, 52.70, 44.14, 13.55. HRMS (ESI) Calcd. for C₄₀H₃₆N₂NaO₆ (M+Na)⁺ 663.2471, found: 663.2459.


(S)-ethyl 2-((R)-1-benzyl-3-(4-(dibenzylamino)phenyl)-5-fluoro-2-oxoindolin-3-yl)-2-hydroxyacetate



syn-4d

¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.26 (m, 10H), 7.25 – 7.18 (m, 7H), 6.98 – 6.91 (m, 1H), 6.90 – 6.83 (m, 1H), 6.68 (d, *J* = 8.3 Hz, 2H), 6.61 – 6.52 (m, 1H), 5.12 (d, *J* = 9.0 Hz, 1H), 5.05 (d, *J* = 15.9 Hz, 1H), 4.73 (d, *J* = 15.9 Hz, 1H), 4.64 (s, 4H), 4.04 – 3.89 (m, 2H), 3.49 (d, *J* = 9.1 Hz, 1H), 0.89 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 176.49, 171.88, 152.68, 142.43, 139.79, 139.09, 135.02, 128.92, 128.83, 128.61, 128.28, 128.20, 128.15, 127.70, 127.63, 127.11, 126.76, 126.60, 120.13, 119.64, 111.63, 110.59, 75.23, 61.65, 59.25, 55.59, 44.17, 13.66. ¹⁹F NMR (376 MHz, CDCl₃) δ -120.31. HRMS (ESI) Calcd. for C₃₉H₃₅N₂NaO₄F (M+Na)⁺ 637.2479, found: 637.2452.

(S)-ethyl 2-((R)-1-benzyl-5-chloro-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate




syn-4e

¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.09 (m, 19H), 6.68 (d, *J* = 8.8 Hz, 2H), 6.57 (d, *J* = 8.3 Hz, 1H), 5.11 (d, *J* = 9.2 Hz, 1H), 5.06 (d, *J* = 15.9 Hz, 1H), 4.72 (d, *J* = 15.9 Hz, 1H), 4.64 (s, 4H),


4.06 – 3.75 (m, 2H), 3.49 (d, J = 9.2 Hz, 1H), 0.90 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 176.82, 171.91, 148.62, 142.31, 138.34, 135.05, 129.18, 128.81, 128.73, 128.68, 128.37, 127.66, 127.63, 127.15, 127.00, 126.58, 126.48, 122.59, 112.29, 110.53, 75.19, 61.50, 58.76, 54.33, 44.15, 13.58. HRMS (ESI) Calcd. for $\text{C}_{39}\text{H}_{35}\text{N}_2\text{NaO}_4\text{Cl} (\text{M}+\text{Na})^+$ 653.2183, found: 653.2167.

(S)-ethyl 2-((R)-1-benzyl-5-bromo-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate




^1H NMR (400 MHz, CDCl_3) δ 7.32 – 7.20 (m, 19H), 6.68 (d, J = 8.8 Hz, 2H), 6.53 (d, J = 8.2 Hz, 1H), 5.11 (d, J = 9.3 Hz, 1H), 5.05 (d, J = 15.9 Hz, 1H), 4.72 (d, J = 15.9 Hz, 1H), 4.65 (s, 4H), 4.19 – 3.80 (m, 2H), 3.49 (d, J = 9.3 Hz, 1H), 0.91 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 171.87, 148.63, 142.78, 138.34, 135.01, 131.63, 129.60, 129.18, 128.81, 128.68, 128.36, 127.67, 127.15, 127.01, 126.58, 122.58, 114.93, 112.30, 111.04, 75.22, 61.51, 58.70, 54.33, 44.12, 13.60. HRMS (ESI) Calcd. for $\text{C}_{39}\text{H}_{35}\text{N}_2\text{NaO}_4\text{Br} (\text{M}+\text{Na})^+$ 697.1678, found: 697.1664.

(S)-ethyl 2-((R)-1-benzyl-3-(4-(dibenzylamino)phenyl)-5-methyl-2-oxoindolin-3-yl)-2-hydroxyacetate




^1H NMR (400 MHz, CDCl_3) δ 7.36 – 7.19 (m, 17H), 7.04 – 6.89 (m, 2H), 6.67 (d, J = 8.5 Hz, 2H), 6.55 (d, J = 7.9 Hz, 1H), 5.11 (d, J = 9.6 Hz, 1H), 5.02 (d, J = 15.8 Hz, 1H), 4.76 (d, J = 15.8 Hz, 1H), 4.63 (s, 4H), 4.07 – 3.80 (m, 2H), 3.60 (d, J = 9.6 Hz, 1H), 2.29 (s, 3H), 0.87 (t, J = 7.0 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 177.26, 172.07, 148.45, 141.27, 138.48, 135.64, 131.64, 129.07, 128.67, 128.64, 128.48, 127.43, 127.21, 126.94, 126.82, 126.61, 123.67, 112.22, 109.37, 77.34, 77.02, 76.71, 75.46, 61.17, 58.40, 54.29, 44.05, 21.22, 13.55. HRMS (ESI) Calcd. for $\text{C}_{40}\text{H}_{38}\text{N}_2\text{NaO}_4 (\text{M}+\text{Na})^+$ 633.2729, found: 633.2708.

(S)-ethyl 2-((R)-1-benzyl-6-chloro-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate




¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.20 (m, 17H), 7.11 – 7.05 (m, 1H), 7.03 – 6.97 (m, 1H), 6.66 (d, *J* = 7.4 Hz, 3H), 5.11 (d, *J* = 9.1 Hz, 1H), 5.04 (d, *J* = 15.9 Hz, 1H), 4.73 – 4.60 (m, 5H), 4.10 – 3.85 (m, 2H), 3.33 (d, *J* = 9.1 Hz, 1H), 0.89 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 177.15, 172.08, 148.57, 145.14, 138.36, 134.95, 134.71, 128.85, 128.66, 128.42, 127.70, 127.12, 127.04, 126.99, 126.58, 125.50, 122.62, 122.03, 112.23, 110.14, 75.16, 61.48, 58.48, 54.32, 44.13, 13.57. HRMS (ESI) Calcd. for C₃₉H₃₅N₂NaO₄Cl (M+Na)⁺ 653.2183, found: 653.2169.

(S)-ethyl 2-((R)-1-benzyl-6-bromo-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate



¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.24 (m, 13H), 7.23 – 7.14 (m, 5H), 7.06 – 6.99 (m, 1H), 6.88 – 6.78 (m, 1H), 6.66 (d, *J* = 8.2 Hz, 2H), 5.11 (d, *J* = 8.8 Hz, 1H), 5.03 (d, *J* = 15.9 Hz, 1H), 4.77 – 4.58 (m, 5H), 4.08 – 3.83 (m, 2H), 3.33 (d, *J* = 8.9 Hz, 1H), 0.90 (t, *J* = 6.7 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 177.03, 172.06, 148.57, 145.27, 138.35, 134.93, 128.85, 128.65, 128.40, 127.70, 127.39, 127.10, 126.99, 126.58, 126.08, 124.98, 122.56, 122.50, 112.88, 112.23, 75.09, 61.48, 58.55, 54.32, 44.11, 13.57. HRMS (ESI) Calcd. for C₃₉H₃₅N₂NaO₄Br (M+Na)⁺ 697.1678, found: 697.1649.


(S)-ethyl 2-((R)-3-(4-(dibenzylamino)phenyl)-5-fluoro-1-methyl-2-oxoindolin-3-yl)-2-hydroxyacetate



¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.25 (m, 6H), 7.24 – 7.17 (m, 6H), 7.05 – 6.96 (m, 2H), 6.79 – 6.73 (m, 1H), 6.68 – 6.59 (m, 2H), 5.03 (d, *J* = 6.0 Hz, 1H), 4.62 (s, 4H), 4.02 – 3.85 (m, 2H), 3.60 (d, *J* = 7.6 Hz, 1H), 3.17 (s, 3H), 0.90 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ

176.94, 171.90, 158.77 (d, $J = 240.9$ Hz), 148.56, 140.63, 138.36, 129.10, 129.02, 128.70, 128.33, 127.01, 126.63, 126.58, 122.69, 115.20 (d, $J = 23.4$ Hz), 114.26 (d, $J = 25.2$ Hz), 112.23, 108.91 (d, $J = 8.1$ Hz), 75.26, 61.38, 58.61, 54.34, 26.66, 13.63. ^{19}F NMR (376 MHz, CDCl_3) δ -120.26. HRMS (ESI) Calcd. for $\text{C}_{33}\text{H}_{32}\text{N}_2\text{O}_4\text{F}$ ($\text{M}+\text{H}$) $^+$ 539.2346, found: 539.2350.


(S)-ethyl 2-((R)-5-bromo-3-(4-(dibenzylamino)phenyl)-1-methyl-2-oxoindolin-3-yl)-2-hydroxyacetate



syn-4k

^1H NMR (400 MHz, CDCl_3) δ 7.48 – 7.39 (m, 1H), 7.36 – 7.16 (m, 13H), 6.72 (d, $J = 8.3$ Hz, 1H), 6.65 (d, $J = 9.0$ Hz, 2H), 5.01 (d, $J = 9.5$ Hz, 1H), 4.63 (s, 4H), 4.04 – 3.84 (m, 2H), 3.58 (d, $J = 9.5$ Hz, 1H), 3.17 (s, 3H), 0.92 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 176.66, 171.80, 148.60, 143.67, 138.32, 131.77, 129.64, 129.13, 128.69, 128.33, 127.01, 126.56, 122.49, 114.90, 112.25, 109.89, 75.30, 61.42, 58.34, 54.33, 26.61, 13.64. HRMS (ESI) Calcd. for $\text{C}_{33}\text{H}_{31}\text{N}_2\text{NaO}_4\text{Br}$ ($\text{M}+\text{Na}$) $^+$ 621.1365, found: 621.1342.


(S)-ethyl 2-((R)-3-(4-(dibenzylamino)phenyl)-1,5-dimethyl-2-oxoindolin-3-yl)-2-hydroxyacetate



syn-4l

^1H NMR (400 MHz, CDCl_3) δ 7.35 – 7.16 (m, 12H), 7.10 (d, $J = 7.8$ Hz, 1H), 7.02 (s, 1H), 6.73 (d, $J = 7.9$ Hz, 1H), 6.65 (d, $J = 8.9$ Hz, 2H), 5.02 (d, $J = 9.9$ Hz, 1H), 4.62 (s, 4H), 4.02 – 3.81 (m, 2H), 3.73 (d, $J = 9.9$ Hz, 1H), 3.18 (s, 3H), 2.33 (s, 3H), 0.88 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 177.21, 171.95, 148.42, 142.12, 138.46, 131.71, 129.18, 128.65, 128.43, 127.54, 126.94, 126.76, 126.58, 123.60, 112.15, 108.23, 75.59, 61.07, 57.97, 54.29, 26.51, 21.27, 13.60. HRMS (ESI) Calcd. for $\text{C}_{34}\text{H}_{35}\text{N}_2\text{O}_4$ ($\text{M}+\text{H}$) $^+$ 535.2597, found: 535.2586.


(S)-ethyl 2-((R)-1-benzyl-6-chloro-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate



syn-4m

¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.07 (m, 13H), 7.07 – 7.01 (m, 1H), 6.84 (s, 1H), 6.63 (d, *J* = 8.7 Hz, 2H), 5.01 (d, *J* = 9.2 Hz, 1H), 4.61 (s, 4H), 4.08 – 3.80 (m, 2H), 3.42 (d, *J* = 9.2 Hz, 1H), 3.14 (s, 3H), 0.90 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 177.08, 172.04, 148.55, 146.02, 138.39, 134.89, 128.70, 128.43, 127.05, 127.02, 126.59, 125.55, 122.57, 121.99, 112.19, 109.25, 75.25, 61.42, 58.24, 54.35, 26.64, 13.66. HRMS (ESI) Calcd. for C₃₃H₃₂N₂O₄Cl (M+H)⁺ 555.2051, found: 555.2042.


(S)-ethyl 2-((R)-1-benzyl-5-chloro-3-(4-(dibenzylamino)-3-fluorophenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate



syn-4n

¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.10 (m, 18H), 7.01 (d, *J* = 8.1 Hz, 1H), 6.77 (t, *J* = 8.9 Hz, 1H), 6.60 (d, *J* = 8.3 Hz, 1H), 5.15 – 4.95 (m, 2H), 4.73 (d, *J* = 15.9 Hz, 1H), 4.35 (s, 4H), 4.08 – 3.84 (m, 2H), 3.35 (d, *J* = 6.3 Hz, 1H), 0.85 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 176.07, 171.70, 154.75 (d, *J* = 244.6 Hz), 142.48, 138.27, 134.88, 129.16, 128.86, 128.41, 128.15, 127.91, 127.80, 127.75, 127.62, 127.10, 126.44, 123.24 (d, *J* = 2.8 Hz), 120.07 (d, *J* = 3.6 Hz), 116.03 (d, *J* = 23.9 Hz), 110.76, 75.06, 61.79, 58.83, 55.61, 55.57, 44.23, 13.66. ¹⁹F NMR (376 MHz, CDCl₃) δ -121.30. HRMS (ESI) Calcd. for C₃₉H₃₄N₂NaO₄ClF (M+Na)⁺ 671.2089, found: 671.2086.

(S)-ethyl 2-((R)-1-benzyl-5-chloro-3-(4-(dibenzylamino)-3-methoxyphenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate




syn-4o

¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.10 (m, 18H), 6.78 – 6.65 (m, 2H), 6.61 (d, *J* = 8.9 Hz, 1H),


5.14 (d, $J = 8.9$ Hz, 1H), 5.05 (d, $J = 15.9$ Hz, 1H), 4.76 (d, $J = 15.9$ Hz, 1H), 4.25 (s, 4H), 3.98 – 3.81 (m, 5H), 3.37 (d, $J = 8.9$ Hz, 1H), 0.82 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 176.49, 171.89, 152.67, 142.42, 139.78, 139.08, 135.02, 128.93, 128.83, 128.60, 128.28, 128.15, 127.70, 127.62, 127.11, 126.77, 126.60, 120.11, 119.63, 111.61, 110.60, 75.22, 61.65, 59.25, 55.75, 55.59, 44.16, 13.67. HRMS (ESI) Calcd. for $\text{C}_{40}\text{H}_{37}\text{N}_2\text{NaO}_5\text{Cl} (\text{M}+\text{Na})^+$ 683.2289, found: 683.2283.

(S)-ethyl 2-((R)-1-benzyl-3-(4-(benzyl(ethyl)amino)phenyl)-5-chloro-2-oxoindolin-3-yl)-2-hydroxyacetate




^1H NMR (400 MHz, CDCl_3) δ 7.33 – 7.12 (m, 14H), 6.69 – 6.53 (m, 3H), 5.12 (d, $J = 9.3$ Hz, 1H), 5.05 (d, $J = 15.9$ Hz, 1H), 4.75 (d, $J = 15.9$ Hz, 1H), 4.50 (s, 2H), 4.12 – 3.84 (m, 2H), 3.63 – 3.41 (m, 3H), 1.19 (t, $J = 7.0$ Hz, 3H), 0.90 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 176.91, 171.90, 147.99, 142.28, 138.95, 135.10, 129.37, 128.82, 128.69, 128.58, 128.34, 127.66, 127.17, 126.85, 126.46, 121.84, 111.96, 110.52, 75.25, 61.49, 58.68, 53.84, 45.34, 44.14, 13.57, 12.13. HRMS (ESI) Calcd. for $\text{C}_{34}\text{H}_{33}\text{N}_2\text{NaO}_4\text{Cl} (\text{M}+\text{Na})^+$ 591.2027, found: 591.2010.

(S)-ethyl 2-((R)-1-benzyl-5-chloro-3-(4-(diallylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate




^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.12 (m, 9H), 6.75 – 6.52 (m, 3H), 5.91 – 5.72 (m, 2H), 5.24 – 5.00 (m, 6H), 4.75 (d, $J = 15.8$ Hz, 1H), 4.08 – 3.83 (m, 6H), 3.54 (d, $J = 9.2$ Hz, 1H), 0.91 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 176.89, 171.90, 148.27, 142.29, 135.09, 133.68, 129.35, 128.81, 128.70, 128.19, 127.66, 127.16, 126.48, 122.08, 116.03, 112.11, 110.52, 75.25, 61.48, 58.69, 52.70, 44.14, 13.56. HRMS (ESI) Calcd. for $\text{C}_{31}\text{H}_{31}\text{N}_2\text{NaO}_4\text{Cl} (\text{M}+\text{Na})^+$ 553.1870, found: 553.1862.

(S)-methyl 2-((R)-1-benzyl-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate




¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.10 (m, 19H), 7.02 (t, *J* = 7.5 Hz, 1H), 6.73 – 6.63 (m, 3H), 5.14 (d, *J* = 9.6 Hz, 1H), 5.04 (d, *J* = 15.8 Hz, 1H), 4.78 (d, *J* = 15.8 Hz, 1H), 4.62 (s, 4H), 3.70 (d, *J* = 9.6 Hz, 1H), 3.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 177.29, 172.44, 148.59, 143.61, 138.45, 135.54, 128.82, 128.75, 128.67, 128.36, 127.54, 127.28, 126.98, 126.67, 125.90, 123.44, 122.32, 112.39, 109.67, 75.57, 58.22, 54.28, 52.13, 44.08. HRMS (ESI) Calcd. for C₃₈H₃₄N₂NaO₄ (M+Na)⁺ 605.2416, found: 605.2421.

(S)-isopropyl 2-((R)-1-benzyl-3-(4-(dibenzylamino)phenyl)-2-oxoindolin-3-yl)-2-hydroxyacetate



¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.13 (m, 19H), 7.01 (t, *J* = 7.5 Hz, 1H), 6.70 – 6.59 (m, 3H), 5.10 (d, *J* = 9.5 Hz, 1H), 5.04 (d, *J* = 15.9 Hz, 1H), 4.89 – 4.71 (m, 2H), 4.63 (s, 4H), 3.44 (d, *J* = 9.5 Hz, 1H), 1.07 (d, *J* = 6.2 Hz, 3H), 0.75 (d, *J* = 6.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 177.33, 171.78, 148.43, 143.85, 138.49, 135.57, 128.80, 128.73, 128.67, 127.48, 127.19, 127.15, 126.97, 126.61, 126.30, 123.40, 122.11, 112.15, 109.66, 75.31, 69.29, 58.70, 54.34, 44.05, 21.55, 21.08. HRMS (ESI) Calcd. for C₄₀H₃₈N₂NaO₄ (M+Na)⁺ 633.2729, found: 633.2739.


1-benzyl-3-(4-(dibenzylamino)phenyl)indolin-2-one



¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.27 (m, 8H), 7.27 – 7.20 (m, 7H), 7.18 – 7.12 (m, 2H), 7.03 – 6.94 (m, 3H), 6.75 – 6.63 (m, 3H), 5.07 – 4.80 (m, 2H), 4.62 (s, 4H), 4.58 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 176.84, 148.67, 143.54, 138.55, 136.05, 129.51, 129.20, 128.76, 128.67, 128.03, 127.56, 127.35, 126.93, 126.68, 125.15, 124.47, 122.59, 112.82, 109.07, 54.29, 51.22, 43.91.

HRMS (ESI) Calcd. for $C_{35}H_{30}N_2NaO$ ($M+Na$)⁺ 517.2256, found: 517.2239.


N,N-dibenzylaniline-d⁵



[D₅]-1a

¹H NMR (400 MHz, CDCl₃) δ 8.71 – 6.60 (m, 10H), 4.64 (s, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 149.14, 138.68, 128.68, 126.92, 126.72, 54.26. HRMS (ESI) Calcd. for C₂₀H₁₅N₁D₅ ($M+H$)⁺ 279.1910, found: 279.1923.


syn-4e-d⁴



syn-[D₄]-4e

¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.12 (m, 17H), 6.57 (d, J = 8.3 Hz, 1H), 5.22 – 4.97 (m, 2H), 4.86 – 4.49 (m, 5H), 4.15 – 3.79 (m, 2H), 3.48 (d, J = 9.1 Hz, 1H), 0.90 (t, J = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 176.82, 171.90, 148.51, 142.31, 138.35, 135.05, 129.17, 128.80, 128.67, 127.65, 127.14, 127.00, 126.57, 126.46, 122.39, 110.51, 75.21, 61.49, 58.71, 54.34, 44.14, 13.57. HRMS (ESI) Calcd. for C₃₉H₃₁D₄N₂NaO₄Cl ($M+Na$)⁺ 657.2434, found: 657.2433.

X-ray Diffraction Parameters and Data of *syn*-4d (CCDC 1480071)



```

Bond precision:      C-C = 0.0089 Å          Wavelength=0.71073
Cell:           a=12.3506(5)     b=15.0930(6)     c=17.7124(7)
                  alpha=90          beta=100.508(2)   gamma=90
Temperature: 296 K

Calculated          Reported
Volume            3246.4(2)          3246.4(2)
Space group       P 21/n            P2(1)/n
Hall group        -P 2yn           ?
Moiety formula   C39 H35 F N2 O4
Sum formula       C39 H35 F N2 O4
Mr                614.69           614.69
Dx, g cm-3       1.258            1.258
Z                 4                 4
Mu (mm-1)         0.085            0.085
F000              1296.0           1296.0
F000'             1296.61          1296.61
h,k,lmax         14,17,21          14,17,21
Nref              5722             5716
Tmin,Tmax        0.979,0.991      0.977,0.991
Tmin'             0.976            0.976

Correction method= # Reported T Limits: Tmin=0.977 Tmax=0.991
AbsCorr = MULTI-SCAN
Data completeness= 0.999          Theta(max)= 25.010
R(reflections)= 0.0818( 2781)    wR2(reflections)= 0.2925( 5716)
S = 1.036          Npar= 404

```

NMR Spectra of Compounds

